Arijan Valar

Mr. Arijan Valar

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 January 2025 in Antioxidants
Verified
Journal Article
Open access
PDF file
MKMarin Kuntic
Marin Kuntic
IKIvana Kuntic
Ivana Kuntic
JZJiayin Zheng
Jiayin Zheng
NLNardi Leonardo
Nardi Leonardo
MOMatthias Oelze
Matthias Oelze
Andreas DaiberAndreas Daiber
Andreas Daiber
Noise pollution is a known health risk factor and evidence for cardiovascular diseases associated with traffic noise is growing. At least 20% of the European Union’s population lives in noise-polluted areas with exposure levels exceeding the recommended limits of the World Health Organization, which is considered unhealthy by the European Environment Agency. This results in the annual loss of 1.6 million healthy life years. Here, we investigated the protective effects of cardiovascular drug interventions against aircraft noise-mediated cardiovascular complications such as elevated oxidative stress or endothelial dysfunction. Using our established mouse exposure model, we applied mean sound pressure levels of 72 dB(A) for 4 d. C57BL/6 mice were treated with the beta-blocker propranolol (15 mg/kg/d s.c. for 5 d) or the alpha-blocker phenoxybenzamine (1.5 mg/kg/d s.c. for 5 d) and noise-exposed for the last 4 d of the drug administration. Short-term noise exposure caused hypertension (measured by tail-cuff blood pressure monitoring) and impaired endothelial function (measured by isometric tension recording in the aorta and video microscopy in cerebral arterioles in response to acetylcholine). Noise also increased markers of oxidative stress and inflammation. Treatment of mice with propranolol and phenoxybenzamine prevented endothelial and microvascular dysfunction, which was supported by a decrease in markers of inflammation and oxidative stress in heart tissue and the brain. Amelioration of noise-induced hypertension (systolic blood pressure) was not observed, whereas pulse pressure was lowered by trend. This study provides a novel perspective mitigating the adverse effects of noise pollution, especially in vulnerable groups with medication, a rationale for further pharmacological human studies.

1 January 2025 in Redox Experimental Medicine
Verified
Journal Article
Open access
PDF file
Arijan ValarArijan Valar
Arijan Valar
JZJiayin Zheng
Jiayin Zheng
TMThomas Münzel
Thomas Münzel
Andreas DaiberAndreas Daiber
Andreas Daiber
MKMarin Kuntic
Marin Kuntic
Noncommunicable diseases such as cardiovascular disease (CVD) are becoming more prevalent in urbanized and industrialized societies. Classic risk factors such as hypertension are reinforced by behavioral factors such as smoking and diet, and environmental risk factors such as transportation noise and air pollution. Animal studies reveal that noise causes annoyance and sleep disturbance, promoting stress hormone release. Air pollution damages the lung, causing inflammation and oxidative stress that can spread to the circulation and remote organs. Both noise and air pollution converge at the vascular level, causing dysfunction in vascular signaling and atherosclerotic plaque formation. The complex interplay between environmental risk factors and CVD can lead to synergistic health impacts. The present review focusses on the impact of noise and air pollution on the brain–heart axis. Noise causes its primary health effects on the brain by activating the sympathetic nervous system and the hypothalamic–pituitary–adrenal axis and thereby causes neuroinflammation, cerebral oxidative stress and via stress hormone signaling, and also induces cardiovascular damage. Air pollution activates the stress response as a homeostatic stressor. Uptake of (nano)particles into the brain can proceed by migration along the olfactory nerve. Particles in the brain can cause stress responses similar to neuroinflammation and cerebral oxidative stress due to noise. Understanding the negative effects of noise and air pollution on the cardiovascular system could help protect patients with preexisting CVD.

13 January 2026 in Antioxidants
Verified
Journal Article
Open access
PDF file
TJTristan Junglas
Tristan Junglas
Andreas DaiberAndreas Daiber
Andreas Daiber
IKIvana Kuntic
Ivana Kuntic
Arijan ValarArijan Valar
Arijan Valar
JZJiayin Zheng
Jiayin Zheng
MKMarin Kuntic
Marin Kuntic
Particulate matter (PM) is a significant contributor to air pollution-associated negative health effects, and cardiovascular disease patients are more susceptible to air pollution-mediated damage of the heart and vessels. The present study investigated the protective effects against PM-induced cardiovascular damage by classic cardiovascular drugs, as used for the standard therapy of cardiovascular disease patients. Male C57BL/6J mice were exposed to ambient PM2.5 (<2.5 µm) for 3 days with or without treatment with the cholesterol-lowering drug atorvastatin (20 mg/kg/d) or the angiotensin-converting enzyme (ACE) inhibitor captopril (50 mg/kg/d). Both drugs mitigated PM2.5-induced systolic blood pressure increases and partially prevented endothelial dysfunction, as reflected by a mixed effect on endothelial nitric oxide synthase phosphorylation. Both drugs ameliorated reactive oxygen species (ROS) formation and phagocytic nicotinamide adenine dinucleotide phosphate (NADPH) oxidase (NOX-2) expression in the vasculature of PM2.5-exposed mice. Pulmonary ROS levels showed a minor improvement by the treatments, whereas Nox2 mRNA expression was not diminished. Only captopril showed some anti-inflammatory effects in the heart and lung of PM2.5-exposed mice, whereas both drugs failed to reduce systemic inflammation measured in plasma. These findings offer new insights into potential mitigation strategies for PM2.5-induced cardiovascular complications, particularly for patients at higher cardiovascular risk, like those with coronary artery or ischemic heart disease or hypertension.